Information Provided By: 
Fly News Breaks for December 13, 2016
DVA
Dec 13, 2016 | 07:37 EDT
As previously reported, Baird analyst Whit Mayo downgraded DaVita to Neutral from Outperform after CMS issued its notice with respect to third-party premium support for ESRD patients enrolling in Exchange plans, which he views as potentially putting the company's entire $230M HIX tailwind at risk. Mayo, who also cites the stock's 20% bounce off of its bottom and the company's "tepid" organic growth, sees DaVita shares "trading sideways" in the near-term. He raised his price target on DaVita to $69 from $68.
News For DVA From the Last 2 Days
There are no results for your query DVA
